Glenmark Pharma gets USFDA approval for Regadenoson Injection; Stock stays steady

17 Jan 2022 , 12:57 PM

Glenmark Pharmaceuticals Ltd stocks in focus on Monday after Glenmark Pharmaceuticals Inc., USA (Glenmark) has received tentative approval by the United States Food & Drug Administration (U.S. FDA) for Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL) Single-Dose Pre-Filled Syringe, the generic version of Lexiscan Injection, 0.4 mg/5 mL (0.08 mg/mL), of Astellas US, Inc.

According to IQVIATM sales data for the 12 month period ending November 2021, the Lexiscan Injection, 0.4 mg/5 mL (0.08 mg/mL) market achieved annual sales of approximately $659.9 million.

Glenmark’s current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 47 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

At around 12:58 PM, Glenmark Pharma was trading at Rs516.60 per piece up by Rs0.6 or 0.12% on the BSE. The scrip touched intraday high and intraday low at Rs519.0 per piece and Rs505 per piece.